S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:CKPT

Checkpoint Therapeutics (CKPT) Stock Price, News & Analysis

$2.05
+0.01 (+0.49%)
(As of 03/28/2024 ET)
Today's Range
$2.02
$2.10
50-Day Range
$1.68
$2.32
52-Week Range
$1.30
$3.91
Volume
345,753 shs
Average Volume
588,945 shs
Market Capitalization
$48.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.60

Checkpoint Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,002.4% Upside
$22.60 Price Target
Short Interest
Bearish
18.20% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.63
Upright™ Environmental Score
News Sentiment
-0.23mentions of Checkpoint Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$48,297 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.26 out of 5 stars

Medical Sector

306th out of 938 stocks

Pharmaceutical Preparations Industry

134th out of 425 stocks

CKPT stock logo

About Checkpoint Therapeutics Stock (NASDAQ:CKPT)

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

CKPT Stock Price History

CKPT Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
CKPT Checkpoint Therapeutics, Inc.
Checkpoint Therapeutics, Inc. (CKPT)
Checkpoint Therapeutics to raise ~$14M
See More Headlines
Receive CKPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Checkpoint Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/22/2024
Today
3/28/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CKPT
Fax
N/A
Employees
24
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$22.60
High Stock Price Target
$47.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+1,002.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-51,850,000.00
Net Margins
-50,336.89%
Pretax Margin
-50,336.89%

Debt

Sales & Book Value

Annual Sales
$100,000.00
Book Value
($1.89) per share

Miscellaneous

Free Float
22,491,000
Market Cap
$48.24 million
Optionable
Optionable
Beta
1.00
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

CKPT Stock Analysis - Frequently Asked Questions

Should I buy or sell Checkpoint Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CKPT shares.
View CKPT analyst ratings
or view top-rated stocks.

What is Checkpoint Therapeutics' stock price target for 2024?

5 brokers have issued 12-month price objectives for Checkpoint Therapeutics' stock. Their CKPT share price targets range from $4.00 to $47.00. On average, they predict the company's stock price to reach $22.60 in the next twelve months. This suggests a possible upside of 1,002.4% from the stock's current price.
View analysts price targets for CKPT
or view top-rated stocks among Wall Street analysts.

How have CKPT shares performed in 2024?

Checkpoint Therapeutics' stock was trading at $2.29 on January 1st, 2024. Since then, CKPT shares have decreased by 10.5% and is now trading at $2.05.
View the best growth stocks for 2024 here
.

Are investors shorting Checkpoint Therapeutics?

Checkpoint Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 3,670,000 shares, an increase of 9.6% from the February 29th total of 3,350,000 shares. Based on an average trading volume of 654,100 shares, the short-interest ratio is currently 5.6 days. Approximately 18.2% of the company's stock are sold short.
View Checkpoint Therapeutics' Short Interest
.

When is Checkpoint Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our CKPT earnings forecast
.

How were Checkpoint Therapeutics' earnings last quarter?

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) issued its quarterly earnings data on Friday, March, 22nd. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.74) by $0.36. The firm had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.09 million.

When did Checkpoint Therapeutics' stock split?

Shares of Checkpoint Therapeutics reverse split on Sunday, December 4th 2022. The 1-10 reverse split was announced on Sunday, December 4th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, December 4th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Checkpoint Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Checkpoint Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX), Kadmon (KDMN) and Rigel Pharmaceuticals (RIGL).

Who are Checkpoint Therapeutics' major shareholders?

Checkpoint Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (10.31%), Vanguard Group Inc. (2.33%), Vanguard Group Inc. (2.33%), B. Riley Wealth Advisors Inc. (0.69%), Northern Trust Corp (0.17%) and Simplex Trading LLC (0.00%). Insiders that own company stock include James F Oliviero III and William Garrett Gray.
View institutional ownership trends
.

How do I buy shares of Checkpoint Therapeutics?

Shares of CKPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CKPT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners